NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or ...

Sunyani Senior High School has booked a comfortable slot in the one-eighth stage of the 2025 National Science and Maths Quiz (NSMQ) after securing a commanding 56 points in their preliminary contest ...

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX) ...

We recently published 10 Big Names With Whopping Gains; 6 Jump All-Time Highs. Akero Therapeutics, Inc. (NASDAQ:AKRO) is one of the best performers on Thursday. Akero Therapeutics saw its share prices ...

Fintel reports that on October 10, 2025, Wolfe Research downgraded their outlook for Akero Therapeutics (NasdaqGS:AKRO) from Outperform to Peer Perform. Analyst Price Forecast Suggests 40.09% Upside ...

Viking Therapeutics (NASDAQ:VKTX) and other biotechs advancing drugs for a liver disease called metabolic dysfunction-associated steatohepatitis (MASH) gained on Thursday as the MASH space witnessed ...

Bernard Nii Martei Korley, a former parliamentary aspirant of the National Democratic Congress (NDC) for the Ledzokuku Constituency, has launched the Akro Heritage Fund, a community-centered ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Akero Therapeutics, Inc. (AKRO) one of those stocks right now ...